Product Name: Vortioxetine hydrobromide
Synonyms: 1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine hydrobromide;Lu AA21004 (HBr);Lu AA 21004 hydrobromide;Vortioxetine hydrobromide;Vortioxetine (Lu AA21004) hydrobroMide;Vortioxetine (Lu AA21004) HBr;Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-, hydrobromide (1:1);LU AA 21004 HYDROBROMIDE;LU AA21004 HYDROBROMIDE;LU AA21004 HBR;VORTIOXETINE HBR
CAS: 960203-27-4
MF: C18H23BrN2S
MW: 379.36
EINECS: 120-321-1
Product Categories: 5-HT antagonist;Serotonin transporter inhibitor;Inhibitors;API;960203-27-4
Vortioxetine HBr is a new type of diaryl sulfanyl amine antidepressants developed by Japan Takeda and Denmark Lundbeck for the treatment of depression and anxiety. FDA was admitted to be on American market in September 2013 with trade name Brintellix used for the treatment of severe depression in adults and in October of the same year, the admittance application of Vortioxetine to be listed (MAA) received positive comments from European Medicines Agency (EMA) Human Medicines Products Committee (CHMP). CHMP advised to approve of Brintellix being used for the treatment of adult patients with severe depression (MDD). The EMA European Commission granted Vortioxetine the right to be sold throughout the EU in December 2013 with four dose forms,5 mg, 10 mg, 15 mg and 20 mg. Vortioxetine hydrobromide now has applied to be listed in a number of countries except in China.
China
